Scynexis (SCYX) Operating Leases (2019 - 2026)
Scynexis' (SCYX) quarterly Operating Leases came in at $1.4 million in Q2 2026, down 27.04% on a YoY basis from $1.9 million in Q2 2025, and down 8.86% quarter-over-quarter from $1.6 million in Q1 2026.
Analysis
Scynexis (SCYX) Operating Leases (2019 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Operating Leases for 8 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Leases fell 27.04% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (down 27.04% YoY), and the FY2025 full-year result was $1.7 million, down 22.21% from the prior year.
- Operating Leases retreated to $1.4 million in Q2 2026 per SCYX's latest filing, from $1.6 million in the prior quarter.
- Across five years, Operating Leases topped out at $3.1 million in Q1 2022 and bottomed at $1.4 million in Q2 2026.
- Historically, Operating Leases has averaged $2.4 million across 5 years, with a median of $2.4 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Operating Leases decreased 2.4% in 2022, then retreated 27.04% in 2026.
- Over 5 years, Operating Leases stood at $2.9 million in 2022, then declined by 11.64% to $2.6 million in 2023, then declined by 15.73% to $2.2 million in 2024, then fell by 22.21% to $1.7 million in 2025, then retreated by 16.13% to $1.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $1.4 million, $1.6 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.42 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.69 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 2.49 Mn |
| Dec 31, 2023 | 2.58 Mn |
| Sep 30, 2023 | 2.67 Mn |
| Jun 30, 2023 | 2.76 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 3.07 Mn |
| Mar 31, 2022 | 3.14 Mn |
| Dec 31, 2021 | 3.20 Mn |
| Sep 30, 2021 | 3.27 Mn |